ArticleHaematologica2018
CDCA7 is a critical mediator of lymphomagenesis that selectively regulates anchorage-independent growth.
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Unveiling hypoxic regulatory networks by bioinformatics: mechanisms of hypoxia-related hub genes driving rituximab resistance and poor prognosis in DLBCL.Frontiers in oncology · 2025Article
- The ICF syndrome protein CDCA7 harbors a unique DNA binding domain that recognizes a CpG dyad in the context of a non-B DNA.Science advances · 2024Article
- Glutathione overproduction mediates lymphoma initiating cells survival and has a sex-dependent effect on lymphomagenesis.Cell death & disease · 2024Article
- Gene dysregulation in acute HIV-1 infection - early transcriptomic analysis reveals the crucial biological functions affected.Frontiers in cellular and infection microbiology · 2023Article
- Article
- The roles of the cell division cycle-associated gene family in hepatocellular carcinoma.Journal of gastrointestinal oncology · 2021Article
- Article
- Review
- High expression of CDCA7 predicts tumor progression and poor prognosis in human colorectal cancer.Molecular medicine reports · 2020Article
- LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.Cell cycle (Georgetown, Tex.) · 2020Article
- CDCA7 finely tunes cytoskeleton dynamics to promote lymphoma migration and invasion.Haematologica · 2020Article
- The diagnostic and prognostic value of cell division cycle associated gene family in Hepatocellular Carcinoma.Journal of Cancer · 2020Article
- Comprehensive analysis of the expression and prognosis for CDCAs in head and neck squamous cell carcinoma.PloS one · 2020Article
- Long noncoding RNA FGD5-AS1 promotes colorectal cancer cell proliferation, migration, and invasion through upregulating CDCA7 via sponging miR-302e.In vitro cellular & developmental biology. Animal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor formation involves the acquisition of numerous capacities along the progression from a normal cell into a malignant cell, including limitless proliferation (immortalization) and anchorage-independent growth, a capacity that correlates extremely well with tumorigenesis. Great efforts have been made to uncover genes involved in tumor formation, but most genes identified participate in processes related to cell proliferation. Accordingly, therapies targeting these genes also affect the proliferation of normal cells. To identify potential targets for therapeutic intervention more specific to tumor cells, we looked for genes implicated in the acquisition of anchorage-independent growth and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.